RecruitingNot ApplicableNCT07064577

Novel ROS-scavenging Nanoenzymes for the Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer


Sponsor

West China Hospital

Enrollment

30 participants

Start Date

Jul 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

There is no standard treatment for radiation dermatitis. In this study, the investigators have designed novel ROS-scavenging nanoenzymes and aim to evaluate their effectiveness in preventing radiation dermatitis in patients with head and neck cancer.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study tests a nanoenzyme skin cream — tiny engineered particles that neutralize harmful free radicals — as a treatment for radiation dermatitis (a painful skin reaction) in people with head and neck cancer undergoing high-dose radiotherapy. **You may be eligible if...** - You have been diagnosed with a non-metastatic head and neck cancer confirmed by biopsy - You are scheduled to receive high-dose radiotherapy, either as your main treatment or after surgery **You may NOT be eligible if...** - You are in poor overall health (ECOG performance status above 2) - You already have an open skin wound, rash, or ulceration in the area to be treated - You have an inflammatory or connective tissue skin disorder - You have previously received radiation to the head or neck area Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGROS-scavenging Nanoenzymes

ROS-scavenging nanoenzymes are applied to the treatment area, once daily during radiotherapy.

BEHAVIORALStandard of care

Standard of care


Locations(1)

West China Hospital, Sichuan University

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07064577


Related Trials